Brief: Shanghai Henlius Biotech Says FDA Approves HLX43 For Phase 1 Clinical Trial For Treatment Of Thymic Carcinoma
07/08/2025 12:46
Aug 7 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: FDA APPROVES HLX43 FOR PHASE 1 CLINICAL TRIAL FOR TREATMENT OF THYMIC CARCINOMA Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln